Sacroiliac joint pain is responsible for approximately 15% to 25% of reported back pain, and 15% to 25% of axial low back pain arises from pathologies of the sacroiliac joint [1]. There is still no internationally accepted set of recommendations for managing it and no widely accepted treatment algorithm [2]. That is why confirming the joint as the pain generator comes before any discussion of PRP, bone marrow aspirate concentrate, or Lipogems.
Orthobiologics for the sacroiliac joint are a reasonable subject to discuss and a poor subject to promise. The most recent systematic review of sacroiliac management lists regenerative medicine among the therapies that still need to be explored in high-quality studies [2].
How sacroiliac joint pain presents
Patients typically describe pain that is felt deep near the buttock or low back, and that worsens with standing, walking, or transitions such as rising from a chair. It overlaps heavily with lumbar spine, hip, and pelvic pain syndromes, which is exactly why the presentation alone is not sufficient to make the diagnosis.
The joint transfers weight between the lower extremities and the axial skeleton [1]. When that transfer becomes painful, the symptom pattern rarely points cleanly at a single structure without deliberate testing.
Why diagnostic confirmation comes first
The confirmation gap in real-world practice
In a national analysis of 18,032 US patients who underwent sacroiliac joint fusion between 2010 and 2021, only 45% had received a preoperative diagnostic sacroiliac joint injection, and 18% had undergone a prior lumbar fusion [3]. The mean age was 51 years and 69.8% were women [3].
That 45% figure is the reason this article leads with diagnosis rather than with treatment options. More than half of the patients in that dataset committed to an irreversible procedure without the test that confirms the target.
Utilization is rising faster than the evidence
The same analysis projected an overall increase of 1,100% in US sacroiliac fusion volume, from 1,350 cases in 2021 to a projected 16,195 by the end of 2028 [3]. The authors concluded that establishing evidence-based guidelines, improving diagnostic strategies, and defining indications are imperative to support that growth [3].
What can and cannot be said about orthobiologics here
Platelet-rich plasma
PRP is not a single uniform product. Preparation method, platelet concentration, leukocyte content, and injection technique all vary, and those variations are one reason results are inconsistent across the musculoskeletal literature generally. Leukocyte-rich and leukocyte-poor preparations are discussed as separate choices rather than interchangeable ones.
For the sacroiliac joint specifically, no claim is made here that PRP restores the joint. It is discussed as an option for selected patients whose joint has been confirmed as the pain generator, with defined endpoints and monitoring.
Intraosseous and subchondral approaches
Intraosseous PRP describes a bone-targeted strategy that differs from a soft-tissue or intra-articular injection. Whether a bone-adjacent target is even plausible in a given case depends on the examination and imaging, not on patient preference.
Bone marrow aspirate concentrate and Lipogems
BMAC and Lipogems are part of the orthobiologic set discussed at our orthobiologics service. Which, if any, is appropriate is a function of the confirmed target and the overall plan — not a menu item selected in advance of the workup.
Where injections, denervation, and surgery sit relative to each other
The 2025 systematic review of sacroiliac management describes a progression: conservative options, physiotherapy, lifestyle change, and non-steroidal anti-inflammatory drugs first; then fluoroscopically guided injections and radiofrequency denervation; with surgical fusion usually reserved for cases in which conservative treatment has been ineffective [2]. That review pooled 15 randomized controlled trials, 13 clinical trials, and 10 retrospective studies covering 2,666 patients [2].
Regen.MD follows that same order, and does provide surgery when conservative measures have been exhausted. Surgery is never presented as the opening move.
The metabolic terrain around a painful joint
A joint does not repair in isolation from the body it sits in. Our terrain-first approach reviews metabolic markers alongside structural imaging, because tissue asked to heal in an inflammatory environment responds differently regardless of what is injected into it.
Peptide and longevity medicine topics are discussed in that same educational context. They are clinical subjects, not products for purchase.
What a Clinical Evaluation covers
The evaluation begins with a professional review of your history, imaging, and metabolic data before the session, followed by a physician-led discussion of what appears to be driving the pain and a written roadmap of the sequence and the instruments indicated. Whether orthobiologics belong in that sequence is an output of the evaluation, not an assumption going into it.
Frequently asked questions
Can PRP or BMAC fix sacroiliac joint dysfunction?
There is no good-quality randomized evidence that establishes an orthobiologic injection as an effective treatment for sacroiliac joint pain; the most recent systematic review lists regenerative medicine among the therapies that still need to be explored in high-quality studies. It is discussed as an option for selected patients after the joint has been confirmed as the pain generator, and how that confirmation works is described on our joint dysfunction page.
Why does the diagnostic injection matter so much?
In a national analysis of 18,032 US patients who underwent sacroiliac joint fusion between 2010 and 2021, only 45% had received a preoperative diagnostic SI joint injection. Committing to an irreversible procedure without confirming the target is the failure mode we are trying to avoid, and the reasoning is set out further in the Regen.MD library.
Does metabolic health have anything to do with sacroiliac pain?
Tissue that is being asked to repair itself in an inflammatory metabolic environment behaves differently, which is why markers such as fasting insulin, HbA1c, hs-CRP, and lipids are reviewed as part of the evaluation. Peptides are discussed as a clinical and educational subject in that same context and are not sold as a product — see physician-directed peptide therapy.
Who performs the evaluation?
The Clinical Evaluation is physician-led, and orthobiologic injections are performed under image guidance when the target requires it. Background, training, and board certifications are listed on the profile page for Dr. Gurpreet Singh Padda, MD, MBA, MHP.
Key takeaways
- Sacroiliac joint pain accounts for roughly 15% to 25% of reported back pain and of axial low back pain.
- There is no internationally accepted treatment algorithm for sacroiliac joint pain, and regenerative medicine is listed in the current review literature as a therapy still requiring study.
- Among 18,032 US patients who underwent sacroiliac fusion from 2010 to 2021, only 45% had a preoperative diagnostic sacroiliac injection.
- US sacroiliac fusion volume is projected to rise from 1,350 cases in 2021 to 16,195 by the end of 2028 — an increase the review authors say outpaces the guidelines.
- Conservative care and diagnostic confirmation come first; surgery is provided only after conservative measures are exhausted.
Medically reviewed by Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed August 2026.
This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary, and not every patient is a candidate for the therapies described. Do not start, stop, or change any treatment without consulting your physician. Orthobiologic therapies are not FDA-approved for this indication and are provided as part of physician-directed care.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Sources
- Aranke M, McCrudy G, Rooney K, et al. “Minimally Invasive and Conservative Interventions for the Treatment of Sacroiliac Joint Pain: A Review of Recent Literature.” Orthopedic Reviews, 2022;14(3). https://orthopedicreviews.openmedicalpublishing.org/article/34098-minimally-invasive-and-conservative-interventions-for-the-treatment-of-sacroiliac-joint-pain-a-review-of-recent-literature
- Migliorini F, Lucenti L, Bardazzi T, Bell A, Cocconi F. “Management of sacroiliac joint pain: current concepts.” European Journal of Orthopaedic Surgery & Traumatology, 2025. https://pubmed.ncbi.nlm.nih.gov/40397173/
- Ton A, Mertz K, Abdou M, Hang N, Mills ES, et al. “Nationwide Analysis of Sacroiliac Joint Fusion Trends: Regional Variations in Utilization and Population Characteristics.” Global Spine Journal, 2025;15(2):518–525. https://pmc.ncbi.nlm.nih.gov/articles/PMC11877661/